Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 August 2020 | Story Nitha Ramnath | Photo istock

Within the next five years, 60% of the world’s population will be living in urban areas.  Urban living comes with large-scale economic advantages and society benefits from economies of scale. But, COVID-19 is challenging urban living. We have introduced the term ‘social distancing’ and some policy analysts have even argued for the de-densification of cities.

Join us for a discussion where our panellists will analyse this perceived conflict.

Date: Thursday, 27 August 2020
Time: 14:00 to 15:30 (South African Standard Time – GMT +2)

Please RSVP to Elelwani Mmbadi at mmbadiE@ufs.ac.za  no later than 25 August, upon which you will receive a Skype for Business meeting invite and link to access the webinar.

Speakers: 

Prof Ivan Turok
Dr Geci Karuri-Sebina
Mr Thiresh Govender

Moderator: 
Lochner Marais

News Archive

National Department of Health invests R53.5 million in UFS laboratory
2016-02-04

Description: Dr Derek Litthauer Tags: Dr Derek Litthauer

Dr Derek Litthauer
Photo: Supplied

This year has started off on a high note for Dr Derek Litthauer and his team at the South African National Control Laboratory (NCL) for Biological Products. The National Department of Health has awarded the NCL a contract to the value of R53.5 million to continue testing vaccines for the next three years.

Vaccines are biological medicines used to ensure healthy populations by preventing many diseases. The World Health Organization (WHO) estimates that, worldwide, about 5.2 million children under six years old die annually. Of these deaths, 29% are vaccine preventable. Research has revealed that vaccines prevent about 6 million deaths each year globally. Safe and effective vaccines are essential public health tools, which are strictly regulated internationally. It is the NCL’s responsibility to perform quality control testing on all vaccines to be used on humans in South Africa.

This laboratory, the only one of its kind in Africa, receives samples of vaccines from manufacturers and importers for rigorous evaluation and testing. No vaccine may be used in South Africa without a release certificate issued by the Control Lab, certifying that the vaccine is suitable for human use.

The contract is a commitment to ensuring that only vaccines of the highest quality are used in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept